NEW YORK, July 27, 2017 /PRNewswire/ --
If you want a Stock Review on VWR, DGX, LH, or PKI then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. As access to health care expands around the world, the need for diagnostic and research laboratory services will also increase. Growth in the industry is impacted by aging populations and rising demand
On Wednesday, shares in Radnor, Pennsylvania-based VWR Corp. recorded a trading volume of 2.06 million shares, which was above their three months average volume of 1.35 million shares. The stock ended the session 0.15% lower at $32.95. The Company's shares have gained 0.09% in the last one month, 16.72% over the previous three months, and 31.64% on an YTD basis. The stock is trading 15.30% above its 200-day moving average. Moreover, shares of VWR, which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have a Relative Strength Index (RSI) of 47.02. The free research report on VWR is available at:
Madison, New Jersey headquartered Quest Diagnostics Inc.'s stock closed the day 0.04% higher at $108.22. A total volume of 1.47 million shares was traded, which was above their three months average volume of 861,510 shares. The Company's shares have advanced 2.33% in the previous three months and 17.76% since the start of this year. The stock is trading 11.48% above its 200-day moving average. Additionally, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 42.66.
On July 25th, 2017, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On July 25th, 2017, Quest Diagnostics announced financial results for Q2 ended June 30th, 2017. Revenues for Q2 2017 were $1.94 billion; diluted EPS was $1.37; and diluted EPS on an adjusted basis, excluding amortization, was $1.55. The Company also raised its outlook for full-year 2017. Revenues, diluted EPS, and cash provided by operations are expected to be between $7.69 billion and $7.74 billion; between $4.90 and $5.00; and approximately $1.2 billion, respectively. The complimentary report on DGX can be downloaded at:
Laboratory Corp. of America
Shares in Burlington, North Carolina headquartered Laboratory Corp. of America Holdings ("LabCorp") recorded a trading volume of 1.50 million shares, which was above their three months average volume of 688,940 shares. The stock ended yesterday's trading session 2.70% higher at $161.17. The Company's shares have advanced 5.82% in the past month, 16.21% in the previous three months, and 25.54% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.14% and 16.86%, respectively. Furthermore, shares of LabCorp, which operates as an independent clinical laboratory company worldwide, have an RSI of 76.31.
On June 27th, 2017, research firm KeyBanc Capital Markets downgraded the Company's stock rating from 'Overweight' to 'Sector Weight'.
On July 11th, 2017, LabCorp and Novant Health have agreed to a multi-year extension of their Technical Services Agreement, which was first implemented in 2012. Under the agreement, LabCorp Diagnostics provides the latter with laboratory management services for all Novant Health acute care facilities. Visit us today and download our complete research report on LH for free at:
Waltham, Massachusetts headquartered PerkinElmer Inc.'s stock finished Wednesday's session 3.14% lower at $66.09. A total volume of 1.52 million shares was traded, which was above their three months average volume of 591,830 shares. The Company's shares have advanced 10.19% over the previous three months and 26.73% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.10% and 15.30%, respectively. Additionally, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have an RSI of 37.76.
On July 13th, 2017, research firm Wells Fargo initiated a 'Market Perform' rating on the Company's stock.
On July 24th, 2017, PerkinElmer's Board of Directors declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 10th, 2017, to all shareholders of record at the close of business on October 20th, 2017. Get free access to your technical report on PKI at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All